M-CENK adoptive cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for M-CENK adoptive cell therapy, covering 2025-10-20 to 2025-10-20. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer [Phase 2]